# Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)

> **NCT04742738** · PHASE1,PHASE2 · COMPLETED · sponsor: **SK Bioscience Co., Ltd.** · enrollment: 260 (actual)

## Conditions studied

- COVID-19 (Healthy Volunteers)

## Interventions

- **BIOLOGICAL:** GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1
- **OTHER:** Normal saline (0.9% sodium chloride solution) - Stage 1
- **BIOLOGICAL:** GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1
- **OTHER:** Normal saline (0.9% sodium chloride solution) - Stage 1
- **BIOLOGICAL:** GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2
- **BIOLOGICAL:** GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2
- **OTHER:** Normal saline (0.9% sodium chloride solution)- Stage 2

## Key facts

- **NCT ID:** NCT04742738
- **Lead sponsor:** SK Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2021-07-30
- **Final completion:** 2022-07-07
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04742738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04742738, "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04742738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*